Naprelan (naproxen sodium)

Company
Elan Pharmaceuticals, Wyeth

Approval Status
Approved January 1996

Treatment for
osteoarthritis, rheumatoid arthritis

Areas
Diabetes / Endocrinology , Musculoskeletal , Rheumatology

Naprelan (naproxen sodium) is the once-a-day formulation of the arthritis medication Naprosyn (naproxen). Naprelan, a sodium salt formulation of Naprosyn, provides for more rapid absorption.

Naprelan tablets use a proprietary delivery system, IPDAS (Intestinal Protective Drug Absorption System), a matrix of naproxen sodium with immediate and controlled release components. Upon ingestion, and after rapid disintegration of the tablet matrix, an initial fraction (approximately 30%) of the medication is released for rapid systemic absorption achieving onset of analgesic action within 30 minutes. In addition, a sustained-release component of microparticles provide an extended absorption phase that both minimizes local gastrointestinal concentrations and prolongs therapeutic systemic levels of the drug, enabling 24-hour duration of action and once-a-day dosing (2-4).

The most frequent complaints relate to the gastrointestinal tract. In subjects treated chronically with Naprelan, a non-steroidal anti-inflammatory drug, serious gastrointestinal toxicity such as perforation, ulceration, and bleeding can occur.

Naproxen or naproxen sodium-based products account for approximately one in every five prescriptions written for non-steroidal anti-inflammatory drugs in the United States.

Naprelan (naproxen sodium) Drug Information

The Naprelan (naproxen sodium) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top